As Proteomics Gains Ground in Asia, Pall, Others Take Steps to Expand; Is Market Ready for Them? | GenomeWeb

As biotechnology facilities continue to grow in India and China, proteomics technologies have begun gaining traction there both as R&D components for drug discovery and as part of discovery research in academic centers.

US-based proteomic tool vendors have noticed this trend — not to mention recently enacted intellectual property laws in India meant to woo multinationals — and have taken steps over the past year to gain footholds in those emerging markets.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.